Curated News
By: NewsRamp Editorial Staff
March 30, 2026
BioStem Technologies Advances Nasdaq Uplisting with Audited Financial Filing
TLDR
- BioStem Technologies' Nasdaq uplisting progress offers investors potential for increased stock liquidity and more precise market valuation.
- BioStem Technologies filed audited financial statements for 2024 and 2025, establishing robust reporting processes required for Nasdaq listing compliance.
- BioStem's regenerative medicine advancements using perinatal tissue allografts support clinical applications that improve patient outcomes in various medical specialties.
- BioStem Technologies leverages proprietary BioRetain, CryoTek, and SteriTek technologies to preserve natural tissue properties for medical use.
Impact - Why it Matters
This development matters because a Nasdaq uplisting represents a critical transition for BioStem Technologies from the over-the-counter market to a major national exchange, which typically brings greater investor visibility, improved liquidity, and enhanced credibility. For investors, this could mean more stable trading conditions and potentially increased institutional interest. For the regenerative medicine field, BioStem's growth and potential Nasdaq listing signal confidence in perinatal tissue allograft technologies, which are increasingly important in wound care, orthopedic applications, and surgical procedures. The company's compliance with rigorous financial reporting standards also provides greater transparency for stakeholders evaluating investment opportunities in the rapidly evolving biomedical sector.
Summary
BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company specializing in perinatal tissue allograft products, has taken a significant step toward its goal of uplisting to the Nasdaq exchange. The company announced the filing of its audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2025, which are now available for review on the OTC Markets website. This financial milestone, coupled with recent corporate governance enhancements including the appointment of a new CFO, auditor, and audit committee chair, demonstrates BioStem's commitment to establishing robust financial reporting processes. Chairman and CEO Jason Matuszewski emphasized that listing on Nasdaq remains a top priority, as it would increase the company's visibility, improve stock liquidity, provide more precise market valuation, and enhance its ability to attract top talent.
The company leverages its proprietary BioRetain®, CryoTek®, and SteriTek® processing technologies to develop advanced allograft solutions used by clinicians across various medical specialties. BioStem's quality management system is accredited by the American Association of Tissue Banks and complies with current Good Tissue Practices and Good Manufacturing Processes. The company's portfolio includes the Neox®, Clarix®, VENDAJE®, and American Amnion™ product lines, which support innovation in regenerative medicine. For more information, investors and interested parties can visit biostemtechnologies.com and follow the company on X and LinkedIn, or sign up for the company's email distribution list HERE to stay updated on developments.
This announcement comes through PRISM MediaWire, a trusted press release distribution service, highlighting the company's ongoing efforts to advance its corporate initiatives. The forward-looking statements in the release acknowledge potential risks including competition, technological changes, reimbursement challenges, and general economic factors, but underscore BioStem's confidence in its operational strategies and market penetration. As the company progresses toward its Nasdaq uplisting, this development marks an important phase in BioStem's growth trajectory within the competitive biomedical sector.
Source Statement
This curated news summary relied on content disributed by PRISM Mediawire. Read the original source here, BioStem Technologies Advances Nasdaq Uplisting with Audited Financial Filing
